Novo Nordisk signed an agreement to acquire Cardior to enhance and strengthen its Cardiovascular Disease pipeline through Cardior’s lead assets including CDR132L for heart failure & preclinical assets CDR348T & CDR641L for hypertrophic cardiomyopathy
As per the terms of the agreement, Cardior will receive an aggregate of ~$1.11B as up front, development & commercial milestones
CDR132L is currently being evaluated in the P-II (HFrEF) clinical trial in patients suffering from myocardial infarction, the first patient for which was dosed in Jul 2022. Moreover, Novo expects to initiate a 2nd P-II clinical trial for the evaluation of CDR132L in chronic heart failure patients with cardiac hypertrophy
Ref: Novo Nordisk | Image: Novo Nordisk
Related News:- Neomorph and Novo Nordisk Partner to Discover Molecular Glue Degraders for Cardiometabolic and Rare Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
